Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 586

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 586
---
 further amended to revise the definition of an Approved deSPAC Transaction to have a lock-up of 180 days for directors, officers and 5% or greater stockholders of the post-transaction company.

Third Amendment to the C&E Agreement

On August 29, 2023, the C&E Agreements were further amended to revise the definition of an Approved deSPAC Transaction to remove the minimum cash balance condition of $30 million.

Note 9 – Commitments and Contingencies

The Company may, from time to time, be party to litigation and subject to claims incident to the ordinary course of business. The outcome of litigation and claims cannot be predicted with certainty, and the resolution of any future matters could materially affect the Company’s future financial position, results of operations or cash flows.

Legal fees and other costs associated with such actions are expensed as incurred. The Company assesses, in conjunction with its legal counsel, the need to record a liability for litigation and contingencies. Litigation accruals are recorded when and if it is determined that a loss related matter is both probable and reasonably estimable. Material loss contingencies that are reasonably possible of occurrence, if any, are subject to disclosure. As of December 31, 2023 and 2022, there was no litigation or contingency with at least a reasonable possibility of a material loss. No losses have been recorded during the years ended December 31, 2023 and 2022, respectively, with respect to litigation or loss contingencies.

Note 10 - Subsequent Events

The Company has evaluated subsequent events in connection with the preparation of these financial statements, which is the date the financial statements were issued and determined that there were no significant unrecognized events through that date other than those noted below.

Promissory Notes

On January 16, 2024, the Company issued a $75,000 promissory note to FutureTech Partners, which was subsequently assigned to FutureTech Capital. The promissory note is non-interest bearing and matures on July 16, 2024.

On February 5, 2024, the Company issued a $225,000 promissory note to FutureTech Partners, which was subsequently assigned to FutureTech Capital. The promissory note is non-interest bearing and matures on August 5, 2024.

| F-66 |

longevity biomedical, inc.

notes to the financial statements

December 31, 2023 and 2022

On February 16, 2024,